<DOC>
	<DOCNO>NCT00087490</DOCNO>
	<brief_summary>To determine linezolid superior vancomycin treatment complicate skin soft tissue infection due MRSA adult subject</brief_summary>
	<brief_title>Skin Structure Infections With Suspected Proven Methicillin-Resistant Staphylococcus Aureus ( MRSA )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<criteria>Male female subject sign symptom consistent infection , available , laboratory finding consistent staphylococcal infection ( e.g. , Gram stain culture result ) . Signs symptoms consistent infection Infection suspect due Methicillin Resistant Staphylococcus Aureus Subjects treat previous antibiotic ( systemic topical ) MRSA activity ( linezolid vancomycin ) 24 hour treatment extend 72 hour period prior first dose study drug , unless document treatment failure ( 72 hour treatment respond ) . Subjects uncomplicated skin superficial skin structure infection superficial/simple cellulitis , impetiginous lesion , furuncle , simple abscess need surgical drainage cure . Subjects exclude necrotizing fasciitis , gas gangrene , osteomyelitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>